KHK4827

Phase 1Completed
0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Hype Score

Development Stage

Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Systemic Sclerosis

Conditions

Systemic Sclerosis

Trial Timeline

Oct 6, 2017 → Mar 31, 2025

About KHK4827

KHK4827 is a phase 1 stage product being developed by Kyowa Kirin for Systemic Sclerosis. The current trial status is completed. This product is registered under clinical trial identifier NCT04368403. Target conditions include Systemic Sclerosis.

What happened to similar drugs?

10 of 20 similar drugs in Systemic Sclerosis were approved

Approved (10) Terminated (4) Active (7)
Baricitinib + CyclophosphamideEli LillyApproved
Rosuvastatin + SimvastatinAstraZenecaApproved
AnifrolumabAstraZenecaApproved
EfalizumabMerckApproved
AmbrisentanGilead SciencesApproved
BMS-986165Bristol Myers SquibbApproved
versus hydroxychloroquineSanofiApproved

Hype Score Breakdown

Clinical
6
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (3)

NCT IDPhaseStatus
NCT04368403Phase 1Completed
NCT01782924Phase 3Completed
NCT01782937Phase 3Completed

Competing Products

20 competing products in Systemic Sclerosis

See all competitors
ProductCompanyStageHype Score
Tabalumab Auto-Injector + Tabalumab Prefilled SyringeEli LillyPhase 3
32
Baricitinib + PlaceboEli LillyPhase 2
35
MRA(Tocilizumab) + placeboChugai PharmaceuticalPhase 3
40
MRA(Tocilizumab)Chugai PharmaceuticalPhase 3
40
MRA(Tocilizumab)Chugai PharmaceuticalPhase 3
40
DS-7011a + PlaceboDaiichi SankyoPhase 1
29
DS-7011a + PlaceboDaiichi SankyoPhase 1/2
32
Bocidelpar + PlaceboAstellas PharmaPhase 1
21
Parenteral micafungin application + Other parenteral antifungal drugsAstellas PharmaPre-clinical
26
MicafunginAstellas PharmaPhase 2
35
E6742EisaiPhase 1/2
32
KHK4827 + PlaceboKyowa KirinPhase 3
40
Baricitinib + PlaceboEli LillyPhase 3
40
Baricitinib + CyclophosphamideEli LillyApproved
47
Baricitinib + PlaceboEli LillyPhase 3
32
LY2127399 + Placebo every 2 weeks + Placebo every 4 weeks + Standard of CareEli LillyPhase 3
40
LY3361237 + PlaceboEli LillyPhase 2
27
LY2127399 + PlaceboEli LillyPhase 3
32
LY3361237 + PlaceboEli LillyPhase 1
29
LY2127399 + Placebo every 2 weeks + Placebo every 4 weeksEli LillyPhase 3
40